---
title: "Anavex Life Sciences Gets FDA OK for Clinical Study of Genetic Disorder Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302023466.md"
description: "Anavex Life Sciences received FDA clearance to proceed with a clinical study of blarcamesine (Anavex 2-73) for treating Fragile X syndrome. This approval under an investigational new drug application marks a significant milestone, granting the company open INDs for its three core indications: Alzheimer's Disease, Rett syndrome, and Fragile X syndrome."
datetime: "2026-10-15T20:59:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302023466.md)
  - [en](https://longbridge.com/en/news/302023466.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302023466.md)
generator: "portal-rs"
---

# Anavex Life Sciences Gets FDA OK for Clinical Study of Genetic Disorder Treatment

By Elias Schisgall

Anavex Life Sciences will proceed with a clinical study of a new drug to treat the genetic disorder Fragile X syndrome after getting clearance from U.S. regulators. 

The company said the Food and Drug Administration cleared the study under an investigational new drug application for Anavex 2-73, known generically as blarcamesine. 

The drug had previously been named an orphan drug by the FDA. 

"FDA clearance of the Fragile X IND is an important milestone that gives Anavex open INDs in all three of our core indications: Alzheimer's Disease, Rett syndrome, and Fragile X syndrome, and supports our continued momentum of working closely with the FDA as we move our programs forward," interim Chief Executive Terrie Kellmeyer said. 

Write to Elias Schisgall at elias.schisgall@wsj.com 

(END) Dow Jones Newswires

October 15, 2026 16:49 ET (20:49 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### Related Stocks

- [AVXL.US](https://longbridge.com/en/quote/AVXL.US.md)

## Related News & Research

- [Anavex Completes Clinical Conduct of Two Blarcamesine Pharmacology Studies](https://longbridge.com/en/news/302460977.md)
- [Anavex Receives FDA Clearance for Blarcamesine Trial in Fragile X Syndrome](https://longbridge.com/en/news/302017110.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [Oracle Stocks Edge Up as $1 Billion Backs AI Partners](https://longbridge.com/en/news/302919901.md)
- [Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.](https://longbridge.com/en/news/302948213.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**